

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Phospho-4E-BP1 (Thr37/46) Antibody

RRID:AB_330985

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9459, RRID:AB_330985

Antibody Information

URL: http://antibodyregistry.org/AB_330985

Proper Citation: Cell Signaling Technology Cat# 9459, RRID:AB_330985

Target Antigen: 4E-BP1, phospho (Thr37 / Thr46)

Clonality: unknown

Comments: Applications: W. Consolidation on 10/2018: AB_10078082, AB_10078672, AB_2262165, AB_330985. Info: Used By NYUIHC-581.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-4E-BP1 (Thr37/46) Antibody

Description: This unknown targets 4E-BP1, phospho (Thr37 / Thr46)

Target Organism: rat, mouse, human

Antibody ID: AB_330985

Vendor: Cell Signaling Technology

Catalog Number: 9459

Record Creation Time: 20250819T233625+0000

Record Last Update: 20250820T055125+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-4E-BP1 (Thr37/46) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mahmoud A, et al. (2026) An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis. *Developmental cell*, 61(6), 1289.

Smith MJ, et al. (2026) Persistent Human Quadriceps Muscle Volume Deficits Following ACL Reconstruction Are Associated With No Detectable Between-Leg Differences in Vastus Lateralis Muscle Signaling at Rest or Immediately Following Resistance Exercise. *Scandinavian journal of medicine & science in sports*, 36(7), e70343.

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. *Cell reports*, 45(7), 117559.

Juric D, et al. (2026) PI3K γ Inhibitor and Degradar Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 56.

Choi YK, et al. (2026) The REDD1-NF- κ B-miRNAs-eNOS/SIRT1 axis mediates obesity-induced endothelial cell senescence and hypertension. *Nature communications*, 17(1).

Li G, et al. (2026) Mitochondrial VHL rewires cell metabolism in hypoxia. *Cell metabolism*, 38(1), 174.

Park SJ, et al. (2026) Mechanism by which a linoleic acid metabolite suppresses cancer cell growth by inhibiting mTOR. *Cell chemical biology*, 33(5), 637.

Bakhmet EI, et al. (2026) PCBP1 orchestrates amino acid metabolism burst during the naïve-to-primed pluripotency transition. *Stem cell reports*, 21(7), 102950.

Koshizuka K, et al. (2025) Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. *Cancer*

research, 85(16), 3032.

Mahmoud A, et al. (2025) Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer. *bioRxiv : the preprint server for biology*.

Middleton G, et al. (2025) A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer. *NPJ precision oncology*, 9(1), 67.

Iwamoto Y, et al. (2025) Lactoferrin attenuates renal fibrosis and uremic sarcopenia in a mouse model of adenine-induced chronic kidney disease. *The Journal of nutritional biochemistry*, 146, 110039.

Burgmer S, et al. (2025) Endosymbiont control through non-canonical immune signaling and gut metabolic remodeling. *Cell reports*, 44(6), 115811.

Liu X, et al. (2025) Discovery, delineation, and therapeutic targeting of a hyper-translation pathway driving cytokine release syndrome. *Cell reports. Medicine*, 102531.

Thalalla Gamage S, et al. (2025) Transfer RNA acetylation regulates in vivo mammalian stress signaling. *Science advances*, 11(12), eads2923.

Sadeghi M, et al. (2024) Biased signaling by mutant EGFR underlies dependence on PKC γ in lung adenocarcinoma. *Cell reports*, 43(12), 115026.

Wang X, et al. (2024) The ATAC complex represses the transcriptional program of the autophagy-lysosome pathway via its E3 ubiquitin ligase activity. *Cell reports*, 43(12), 115033.

Thapa N, et al. (2024) A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism. *Cell reports*, 43(5), 114119.

Unachukwu U, et al. (2023) Tyrosine Kinase Inhibitors Diminish Renal Neoplasms in a Tuberous Sclerosis Model Via Induction of Apoptosis. *Molecular cancer therapeutics*, 22(7), 844.

Festa BP, et al. (2023) Microglial-to-neuronal CCR5 signaling regulates autophagy in neurodegeneration. *Neuron*, 111(13), 2021.